Work

346 | Rituximab‐dose‐adjusted Epoch Versus Rituximab‐chop in Primary Mediastinal Large B‐cell Lymphoma

Year: 2025
Type: article
Abstract: mFU of 52 months (5-178) from relapse, 4-year PFS and OS were 37% and 66%, respectively.At first relapse, 30 patients (35%) received autologous stem cell transplantation (ASCT) as consolidation therapy, with a 4-year PFS from ASCT of 76%.36 patients (42%) received CAR-T cell therapy in second or subsequent treatment lines.Of them, 20 patients (56%) achieved prolonged CR, after a mFU from CAR-T infusion of 25 months (5-72) in CR patients.In 24 patients (28%) a checkpoint inhibitor (50% monotherapy) was used as salvage treatment in second or subsequent treatment lines.Five (29%) patients reached sustained CR (mFU of 11 months) without CAR-T or transplant consolidation.Conclusions: Our results indicate that DA-EPOCH-R has significantly higher efficacy than R-CHOP-21 with lower use of RT.The prognosis is good for most patients, even R/R patients seem to have better prognosis than reported in historical series, probably related to new treatment approaches.
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W4411384656
FWCI:
Cites:
Cited by:
Related to: 10